Skip to search formSkip to main contentSkip to account menu

dulaglutide

National Institutes of Health

Related topics

Related topics

9 relations
0.5 ML dulaglutide 3 MG/ML Auto-InjectorGlucagon-Like Peptide 1analogs & derivatives

Broader (4)

Glucagon-Like PeptidesHypoglycemic AgentsImmunoglobulin Fc FragmentsRecombinant Fusion Proteins

Narrower (2)

LY 2189265Trulicity

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study
Aims To report 1-year clinical and economic outcomes from the retrospective DISPEL (Dulaglutide vs Basal InSulin in Injection Na… 
2019
2019
Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
Purpose For patients with type 2 diabetes (T2DM) who remain above their glycemic target on insulin therapy, a combination of… 
2018
2018
Effect of once weekly dulaglutide by baseline beta‐cell function in people with type 2 diabetes in the AWARD programme
Glucagon‐like peptide‐1 receptor agonists lower blood glucose in type 2 diabetes (T2D) partially through glucose‐dependent… 
2018
2018
Comparative effectiveness of once‐weekly glucagon‐like peptide‐1 receptor agonists with regard to 6‐month glycaemic control and weight outcomes in patients with type 2 diabetes
A retrospective cohort study was conducted in patients with type 2 diabetes in an electronic medical record database to compare… 
2018
2018
Comparative usability study of the dulaglutide single-use pen versus the insulin degludec FlexTouch® among self-injection-naïve patients with type 2 diabetes mellitus in Japan
Abstract Objective: This study assessed training time with the dulaglutide single-use pen (SUP) and the insulin degludec… 
Review
2017
Review
2017
Once-weekly administration of dulaglutide, a glucagon-like peptide-1 receptor agonist, as monotherapy and combination therapy: review of the AWARD studies
For the purpose of exploring the development, pharmacology and clinical trial program related to dulaglutide, we conducted a… 
2016
2016
EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.
OBJECTIVE The aim of this post hoc analysis was to assess the efficacy and safety of once-weekly dulaglutide in Hispanic/Latino… 
2016
2016
Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan
Objective The objective of this study was to use a discrete choice experiment (DCE) to estimate patients’ preferences for the… 
2015
2015
DPP-4 inhibitors and risk of heart failure EXAMINEd
Review
2014
Review
2014
Safety and Efficacy of Dulaglutide, a Once Weekly GLP-1 Receptor Agonist, for the Management of Type 2 Diabetes
Abstract Background: Type 2 diabetes (T2D) is an increasingly common endocrine disorder that is characterized by chronic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)